Tharimmune, Inc. (NASDAQ:THAR) Short Interest Down 58.6% in February

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 26,300 shares, a drop of 58.6% from the January 31st total of 63,500 shares. Based on an average daily volume of 95,800 shares, the short-interest ratio is currently 0.3 days. Approximately 1.8% of the company’s stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC purchased a new position in Tharimmune, Inc. (NASDAQ:THAR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned about 2.06% of Tharimmune at the end of the most recent quarter. 1.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

THAR has been the subject of several recent analyst reports. RODMAN&RENSHAW upgraded shares of Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th. Rodman & Renshaw initiated coverage on shares of Tharimmune in a research note on Friday, December 6th. They issued a “buy” rating and a $17.00 target price for the company.

Tharimmune Price Performance

THAR traded down $0.02 during trading on Friday, hitting $1.43. The stock had a trading volume of 49,287 shares, compared to its average volume of 34,843. The stock has a 50 day simple moving average of $1.97 and a two-hundred day simple moving average of $2.30. Tharimmune has a twelve month low of $1.36 and a twelve month high of $7.46.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).